•
Sep 30, 2021

Harrow Q3 2021 Earnings Report

Announced record revenues for the fifth consecutive quarter and reported record levels of other key financial and operational metrics.

Key Takeaways

Harrow Health reported a fifth consecutive quarter of strong top-line revenue growth for Q3 2021. The company also achieved record levels in other key financial and operational metrics.

Reported a fifth consecutive quarter of strong top-line revenue growth.

Achieved record revenue levels.

Reported record levels of other key financial and operational metrics such as revenue per shipping day and total number of product units dispensed.

Announced transactions to further Strategic Vision and drive growth, including the purchase of two drug candidates, AMP-100 and MAQ-100.

Total Revenue
$18.7M
Previous year: $14.4M
+29.9%
EPS
-$0.31
Previous year: $0.32
-196.9%
Gross Profit
$13.8M
Previous year: $10.7M
+28.6%
Cash and Equivalents
$57.7M
Previous year: $5.73M
+906.7%
Free Cash Flow
-$2.37M
Previous year: $2.42M
-197.6%
Total Assets
$103M
Previous year: $59.5M
+72.9%

Harrow

Harrow